ABSTRACT. Data concerning the cardiovascular manifestations of primary hyperparathyroidism (PHPT) are inconsistent, which is due, in part, to the decrease in disease severity over the last several decades. In areas where patients tend to be more symptomatic, data support the presence of cardiovascular findings including myocardial and vascular calcification as well as increased cardiovascular mortality. Data from the cohorts in whom the disease is characterized by mild hypercalcemia, suggest that clinically overt cardiovascular manifestations are unusual in PHPT. Recent data, however, support the presence of subtle cardiovascular manifestations in mild disease, such as changes in endothelial function as well as increased vascular stiffness and perhaps diastolic dysfunction. Left ventricular hypertrophy is a more consistent finding across a spectrum of disease severity, though this finding may be related to hypertension, which has long been associated with PHPT. (J. Endocrinol. Invest. 31: 925-931, 2008) 
INTRODUCTION
There is considerable debate regarding the cardiovascular (CV) manifestations of primary hyperparathyroidism (PHPT) with conflicting data concerning their extent and clinical significance. Many of these apparent disparities may be related to the evolution of the clinical presentation of PHPT over the last 70 years. Once a symptomatic disorder characterized by significant hypercalcemia (1), modern PHPT is frequently asymptomatic, with mild hypercalcemia discovered incidentally on routine biochemical screening (2). As a result, studies of the CV system in PHPT have enrolled populations with varying disease severity, often leading to discrepant findings. Additionally, investigations have explored different parameters of CV health using disparate modalities in patient populations of varying size. When these factors are considered, many of the ostensible inconsistencies within the literature can be resolved. One might anticipate CV effects from PHPT. The biochemical features of PHPT include elevations in serum calcium and PTH, which are both known to affect the CV system. Hypercalcemia has been associated with hypertension, left ventricular hypertrophy (LVH), arrhythmias, vasoconstriction, as well as calcification of the myocardium, heart valves, and coronary arteries (3-8). PTH has been shown to have a vasodilatory effect and to exert direct positive chronotropic and indirect inotropic effects on the heart (9). Data suggest that PTH may also act as a "hypertrophic factor" on myocardial muscle cells, thereby inducing LVH (10). Numerous studies have explored many of these potential mechanisms of CV disease in PH-PT by assessing mortality, hypertension, cardiac conduction abnormalities and arrhythmias, as well as CV structural and functional changes.
MORTALITY
There is ample documentation that CV mortality is increased in patients with severe and moderately severe . The higher mortality rate has been shown to decline with time from parathyroidectomy (PTX), but still persists long after surgical cure, suggesting that PH-PT might cause enduring damage to the CV system (15). The few North American studies that assessed mortality in patients with PHPT have not found mortality to be adversely impacted (16, 17) . In contrast to the European patients described in the studies cited above, PHPT patients diagnosed in Rochester, Minnesota between 1965 and 1992 had lower than expected overall mortality (17). Specifically, CV death rates were strikingly reduced (relative risk 0.6). However, consistent with the European studies, this study did demonstrate that higher maximal serum calcium levels were an independent predictor of mortality. These results are also in accordance with a Swedish investigation indicating that higher serum calcium level, even within the normal range, is an independent predictor of CV mortality (18). One explanation for these incongruent mortality data is that more patients in the US studies had mild disease, with lower serum calcium levels [mean calcium 2.73 mmol/l (10.9 mg/dl)] and fewer symptoms than patients in the European studies, where average calcium levels were significantly higher. This hypothesis is supported by data from Nilsson et al. (19) , who analyzed mortality over a 30 year time period in 10,995 Swedish patients who underwent PTX. While an increased risk of CV mortality was observed in the overall cohort, this risk dissipated in those enrolled later in the study, when the multichannel autoanalyzer allowed diagnosis of the disease in those with no symptoms and lower levels of serum calcium. Hedback et al. (15, 20) also found that survival in Swedish men and women with PHPT who had undergone PTX improved in those with a more recent calendar year of surgery. The decline in death risk paralleled the decrease in mean preoperative serum calcium level over time (15) . While these data do lend credence to the idea that the decline in mortality in more recent years is due to lower calcium levels, there are also other potential interpretations. Among these are the possibilities that increased CV mortality in PHPT is reversed by earlier diagnosis and intervention, or that there was a change in the referral pattern for PTX. Alternatively, newly available treatments for CV abnormalities could explain the findings. Several studies that reported mean serum calcium and risk of death are summarized in Figure 1 . These data suggest that relative risk of CV death in PHPT varies almost linearly with calcium level and that this is a plausible explanation for disparate findings.
HYPERTENSION
Hypertension is frequently seen in association with PH-PT (21-23), even among those with mild disease. While a few studies have shown a reduction in blood pressure immediately after PTX (22, 24), which could be due to the non-specific effects of bed rest or anesthesia, the majority of studies indicate that hypertension is not reversible with surgical cure (21, 25-28). The cause of hypertension in PHPT, still unclear, has been hypothesized to be due to hypomagnesemia (29), increases in catecholamines (30), elevations in renin and aldosterone (31) or vasocontriction (22, 32). Because of uncertainties regarding the mechanism and reversibility of hypertension, the causal relationship between PHPT and hypertension has been questioned. One exception to this rule has been in those patients with multiple endocrine neoplasia, in whom hypertension may be due to catecholamine excess and pheochromcytoma resection curative. As there is no expectation that hypertension will improve in those with sporadic disease, the presence of hypertension in patients with PHPT is not currently an indication for PTX.
CARDIAC CONDUCTION ABNORMALITIES AND ARRYTHMIAS
The shortened QT interval, a well-described consequence of hypercalcemia, creates the potential for cardiac arrhythmia in PHPT (33). There is inconsistent data regarding the presence of cardiac rhythm disturbances in PHPT, but again, this appears to be related to the degree of hypercalcemia in the population studied. A study of pre-operative electrocardiograms in 139 Swedish patients with PHPT [mean calcium 3.03 mmol/l (12.1 mg/dl)] found that serum calcium levels correlated positively with T-wave duration and negatively with QT interval (34, 35). In patients with a similar mean calcium level [2.95 mmol/l (11.8 mg/dl)], Nilsson et al. (36) found a small increase in the number of ventricular extrasystolic beats in those with PHPT, which improved with PTX (36). A small study in patients with more moderate hypercalcemia [mean calcium 2.85 mmol/l (11.4 mg/dl)] confirmed an increase in QT interval after PTX, but found no increased prevalence of supraventricular or ventricular arrhythmias or high-grade AV block (37). QT shortening was not observed in the small study of Barletta et al.
[mean calcium 2.88 mmol/l (11.5 mg/dl)], but only 14 patients with PHPT were studied; they did, however, find evidence of increased sympathetic drive to the heart (38). A recent Italian study, that did not report calcium levels, also found QT shortening and higher sympathetic tone in those with PHPT (39).
CARDIAC STRUCTURAL ABNORMALITIES
Left ventricular hypertrophy LVH, a strong predictor of CV mortality, has been associated with PHPT in most (40-45), but not all (38, 46, 47) , studies across a wide range of calcium levels (2.63-3 mmol/l) (10.5-12 mg/dl). The coexistence of hypertension in many patients with PHPT raises the possibility that any LVH observed in PHPT could be attributable to elevations in blood pressure. However, data suggest that LVH is independent of hypertension (43). Instead, several studies support an association of LVH with PTH level (40, 41, 43) in PHPT. Only one report noted a correlation between left ventricular mass and calcium (42). The higher incidence of LVH in PHPT may be related to increased CV stiffness (48) (See "Vascular function" below) or a direct effect of PTH (10). The issue of the reversibility of CV abnormalities is of significant interest in determining the management implications of these findings. LVH has been found to regress following PTX in a number of studies that have followed patients for at least 6 months post surgery (41, 43, 44) . Studies of shorter duration have not found LVH to improve after PTX (42). Stefenelli et al. reported that regression of LVH was most marked in those without a history of hypertension (44).
Valvular and myocardial calcification
Myocardial and valvular calcifications have clearly been demonstrated in PHPT patients with marked hypercalcemia (44, 49, 50) . Stefenelli et al. reported an increased frequency of aortic (63% vs 12.5%), mitral (49% vs 15%) and myocardial calcification (69% vs 17.5%) in those with PHPT [mean calcium 2.98 mmol/l (11.9 mg/dl)], compared to controls (50). There was no change in valvular or myocardial calcification with PTX. Studies in patients with Relative risk or death ratio 1.8 1.6 1.4 1.2 1 0.8 0.6 0.4 0.2 0 10.7 10.9 11.1 11.3 11.5 11.7 11.9 12.1 12.3 12.5
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